Strang, John http://orcid.org/0000-0002-5413-2725
McDonald, Rebecca
Campbell, Gabrielle http://orcid.org/0000-0002-0851-0748
Degenhardt, Louisa http://orcid.org/0000-0002-8513-2218
Nielsen, Suzanne
Ritter, Alison
Dale, Ola
Article History
First Online: 27 July 2019
Compliance with Ethical Standards
:
: No sources of funding were received for the preparation of this article.
: John Strang, through his university, is working with the pharmaceutical industry to identify new or improved treatments and his employer (King’s College London) has received grants, travel costs and/or consultancy payments; this includes investigation of new naloxone formulations and has included work with in the past 3 years, Martindale, Indivior and Mundipharma (all of whom have naloxone products). His employer (King’s College London) has also registered intellectual property on a novel buccal naloxone formulation, naming John Strang et al., and he was earlier named in a patent registration by a pharmaceutical company regarding a concentrated nasal naloxone spray. John Strang et al. have worked as consultants for the United Nations Office on Drugs and Crime, supporting them with a project introducing take-home naloxone to four central and western Asian countries as well as contributing to local take-home naloxone schemes. For a fuller account, see John Strang’s web-page atExternalRef removed. Rebecca McDonald has undertaken an unpaid student industry placement with Mundipharma Research Ltd. and has received conference-related travel funding and an honorarium from IOTOD (Improving Opioid Outcomes in the Treatment of Opioid Dependence). Rebecca McDonald has been involved in the development of a tablet formulation on which the university (King’s College London) has registered intellectual property. Rebecca McDonald has worked as a consultant for the United Nations Office on Drugs and Crime. Gabrielle Campbell is supported by a National Health and Medical Research Council fellowship (No. 1119992). The National Drug and Alcohol Research Centre at the University of New South Wales is supported by funding from the Australian Government under the Substance Misuse Prevention and Service Improvements Grant Fund. Gabrielle Campbell has received investigator‐initiated untied educational grants from Reckitt Benckiser/Indivior for a study of opioid substitution therapy uptake among patients with chronic non-cancer pain. None of these are directly relevant to the current article. Louisa Degenhardt is supported by National Drug and Alcohol Research Centre research fellowships (No. 1109366 and No. 1041472/No. 1 135 991) and by the National Institutes of Health grant NIDA R01DA1104470. The National Drug and Alcohol Research Centre at the University of New South Wales is supported by funding from the Australian Government under the Drug and Alcohol Program. Louisa Degenhardt has received investigator-initiated untied educational grants from Reckitt Benckiser/Indivior for studies of buprenorphine‐naloxone, buprenorphine depot, naloxone, the development of an opioid‐related behaviour scale and a study of opioid substitution therapy uptake among patients with chronic non‐cancer pain. Louisa Degenhardt has received an untied educational grant from Seqirus for a post‐marketing study of tapentadol and an untied educational grant from Mundipharma for a post‐marketing study of oxycodone. These bodies had no involvement in or knowledge of the current article. Suzanne Nielsen has been a named investigator on untied educational grants from Indivior and Seqirus and has delivered training on opioid dependence for Indivior for which honoraria were paid to her institution. Suzanne Nielsen has participated in an advisory board meeting by Mundipharma relating to naloxone for which she declined a sitting fee. Suzanne Nielsen is a current recipient of a National Health and Medical Research Council Research Fellowship (No. 1163961). Alison Ritter is funded through a National Health and Medical Research Council Research Fellowship (GNT1136944). She has received no funding or untied educational grants from any pharmaceutical company in the last 15 years. This article covers (among others) a naloxone formulation that has been approved by 12 European countries from 16 June, 2018 under the name of Ventizolve<sup>®</sup> (Respinal<sup>®</sup> in Sweden), produced by Sanivo Pharma AS. The sponsor of this trial was AS Den Norske Eterfabrikk. Ola Dale was engaged by AS Den Norske Eterfabrikk as the principal investigator in this study, for which Ola Dale receives no personal honorarium. Ola Dale’s employer, the Norwegian University of Science and Technology and its subsidiary Technical Transfer Office have signed cooperation and licensing contracts with DNE PHARMA to seek commercialisation of this nasal naloxone formulation. This regulates potential royalties for Ola Dale through the Norwegian University of Science and Technology. DNE Pharma AS has compensated Ola Dale for business travel from Trondheim to Oslo.